Related Experiment Videos
Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options
Jeffrey L Cummings1, Gary Tong2, Clive Ballard3
1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Abstract:
Although Alzheimer's disease (AD) is the world's leading cause of dementia and the population of patients with AD continues to grow, no new therapies have been approved in more than a decade. Many clinical trials of single-agent therapies have failed to affect disease progression or symptoms compared with placebo. The complex pathophysiology of AD may necessitate combination treatments rather than monotherapy. The goal of this narrative literature review is to describe types of combination therapy, review the current clinical evidence for combination therapy regimens (both symptomatic and disease-modifying) in the treatment of AD, describe innovative clinical trial study designs that may be effective in testing combination therapy, and discuss the regulatory and drug development landscape for combination therapy. Successful combination therapies in other complex disorders, such as human immunodeficiency virus, may provide useful examples of a potential path forward for AD treatment.
Insights
Alzheimer's disease (AD) treatment requires combination therapies due to complex pathophysiology. This review explores evidence, trial designs, and regulatory aspects for effective AD combination treatments.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Alzheimer's disease (AD) is the leading cause of dementia globally, with a growing patient population.
- No new AD therapies have been approved in over a decade, and many single-agent trials have failed.
- The complex nature of AD pathophysiology suggests combination treatments may be more effective than monotherapy.
Purpose of the Study:
- To review current clinical evidence for combination therapy regimens in Alzheimer's disease (AD).
- To describe innovative clinical trial designs for testing combination therapies.
- To discuss the regulatory and drug development landscape for AD combination treatments.
Main Methods:
- Narrative literature review.
- Analysis of clinical trial data for symptomatic and disease-modifying combination therapies.
- Examination of regulatory pathways and drug development strategies.
Main Results:
- Current evidence for AD combination therapies is limited but evolving.
- Innovative trial designs are needed to efficiently evaluate complex combination regimens.
- Lessons from other complex diseases like HIV may inform AD treatment strategies.
Conclusions:
- Combination therapy represents a promising avenue for future Alzheimer's disease (AD) treatment.
- Further research and novel clinical trial approaches are essential to advance combination therapy development.
- Addressing the complex pathophysiology of AD may require multi-targeted therapeutic strategies.